JP2001509368A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2001509368A5 JP2001509368A5 JP2000501775A JP2000501775A JP2001509368A5 JP 2001509368 A5 JP2001509368 A5 JP 2001509368A5 JP 2000501775 A JP2000501775 A JP 2000501775A JP 2000501775 A JP2000501775 A JP 2000501775A JP 2001509368 A5 JP2001509368 A5 JP 2001509368A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- pro
- peptide
- antibody
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 description 58
- 239000000203 mixture Substances 0.000 description 40
- 102000004196 processed proteins & peptides Human genes 0.000 description 34
- 229920001184 polypeptide Polymers 0.000 description 25
- 108091028043 Nucleic acid sequence Proteins 0.000 description 7
- 150000007523 nucleic acids Chemical group 0.000 description 7
- 125000000217 alkyl group Chemical group 0.000 description 6
- 125000001589 carboacyl group Chemical group 0.000 description 6
- 108010078791 Carrier Proteins Proteins 0.000 description 5
- 102000014914 Carrier Proteins Human genes 0.000 description 5
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 5
- 125000003275 alpha amino acid group Chemical group 0.000 description 5
- 150000001408 amides Chemical class 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 101710149951 Protein Tat Proteins 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 125000006850 spacer group Chemical group 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 3
- 239000012472 biological sample Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- SBKVPJHMSUXZTA-MEJXFZFPSA-N (2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-5-amino-2-[[2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-indol-3-yl)propanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-methylpentanoyl]amino]-5-oxopentanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-5-oxopentanoyl]pyrrolidine-2-carbonyl]amino]-4-methylsulfanylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoic acid Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 SBKVPJHMSUXZTA-MEJXFZFPSA-N 0.000 description 1
- 241000024188 Andala Species 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- 229940021995 DNA vaccine Drugs 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 102000048120 Galactokinases Human genes 0.000 description 1
- 108700023157 Galactokinases Proteins 0.000 description 1
- 102000018932 HSP70 Heat-Shock Proteins Human genes 0.000 description 1
- 108010027992 HSP70 Heat-Shock Proteins Proteins 0.000 description 1
- 101000633984 Homo sapiens Influenza virus NS1A-binding protein Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102100029241 Influenza virus NS1A-binding protein Human genes 0.000 description 1
- 108010038049 Mating Factor Proteins 0.000 description 1
- BAQMYDQNMFBZNA-UHFFFAOYSA-N N-biotinyl-L-lysine Natural products N1C(=O)NC2C(CCCCC(=O)NCCCCC(N)C(O)=O)SCC21 BAQMYDQNMFBZNA-UHFFFAOYSA-N 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- BAQMYDQNMFBZNA-MNXVOIDGSA-N biocytin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)NCCCC[C@H](N)C(O)=O)SC[C@@H]21 BAQMYDQNMFBZNA-MNXVOIDGSA-N 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229960003983 diphtheria toxoid Drugs 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229960000814 tetanus toxoid Drugs 0.000 description 1
- 229940035936 ubiquinone Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/893,853 US5891994A (en) | 1997-07-11 | 1997-07-11 | Methods and compositions for impairing multiplication of HIV-1 |
| US08/893,853 | 1997-07-11 | ||
| PCT/US1998/014332 WO1999002185A1 (en) | 1997-07-11 | 1998-07-10 | Methods and compositions for impairing multiplication of hiv-1 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2001509368A JP2001509368A (ja) | 2001-07-24 |
| JP2001509368A5 true JP2001509368A5 (https=) | 2006-01-19 |
| JP4278293B2 JP4278293B2 (ja) | 2009-06-10 |
Family
ID=25402225
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000501775A Expired - Lifetime JP4278293B2 (ja) | 1997-07-11 | 1998-07-10 | Ｈｉｖの増殖を抑える方法及び組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (6) | US5891994A (https=) |
| EP (1) | EP0994724B1 (https=) |
| JP (1) | JP4278293B2 (https=) |
| AT (1) | ATE413189T1 (https=) |
| AU (1) | AU745012C (https=) |
| CA (1) | CA2295691C (https=) |
| DE (1) | DE69840195D1 (https=) |
| ES (1) | ES2317668T3 (https=) |
| WO (1) | WO1999002185A1 (https=) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG71046A1 (en) * | 1996-10-10 | 2000-03-21 | Connector Systems Tech Nv | High density connector and method of manufacture |
| US5891994A (en) * | 1997-07-11 | 1999-04-06 | Thymon L.L.C. | Methods and compositions for impairing multiplication of HIV-1 |
| US20010008627A1 (en) * | 1999-01-22 | 2001-07-19 | Soll David R. | Hiv-encoded chemoattractant |
| FR2792206B1 (fr) * | 1999-04-13 | 2006-08-04 | Centre Nat Rech Scient | Vaccin anti-vih-1 comprenant tout ou partie de la proteine tat de vih-1 |
| AU4082300A (en) * | 1999-06-21 | 2001-01-09 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Hiv tat peptides and multiple peptide conjugate system |
| US20050226890A1 (en) * | 1999-08-12 | 2005-10-13 | Cohen David I | Tat-based vaccine compositions and methods of making and using same |
| US6399067B1 (en) * | 2000-04-28 | 2002-06-04 | Thymon L.L.C. | Methods and compositions for impairing multiplication of HIV-1 |
| US20080044435A1 (en) * | 2004-03-16 | 2008-02-21 | Cohen David I | Tat-Based Tolerogen Compositions and Methods of Making and Using Same |
| NO314587B1 (no) * | 2000-09-04 | 2003-04-14 | Bionor Immuno As | HIV regulatoriske- og hjelpepeptider, antigener, vaksinepreparater, immunoassay testsett og en metode for påvisning av antistoffer fremkaltav HIV |
| FR2814958B1 (fr) * | 2000-10-06 | 2003-03-07 | Aventis Pasteur | Composition vaccinale |
| AU2002331599A1 (en) * | 2001-08-16 | 2003-03-03 | The General Hospital Corporation | Epitopes of human immunodeficiency virus-1 |
| AU2002365366B2 (en) | 2001-11-21 | 2007-05-10 | The Trustees Of The University Of Pennsylvania | Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use |
| EP1944043A1 (en) | 2001-11-21 | 2008-07-16 | The Trustees of the University of Pennsylvania | Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use |
| WO2003091275A2 (en) * | 2002-04-23 | 2003-11-06 | Andrea Savarino | Compositions containing anti-hiv peptides and methods of use |
| AU2003303197A1 (en) * | 2002-12-18 | 2004-07-14 | University Of Maryland Biotechnology Institute | Vaccines against HIV-TAT protein to generate neutralizing antibodies |
| WO2004084805A2 (en) * | 2003-03-19 | 2004-10-07 | The J. David Gladstone Institutes | Acetylated tat polypeptides and methods of use thereof |
| WO2005062871A2 (en) * | 2003-12-19 | 2005-07-14 | University Of Maryland Biotechnology Institute | Tat linear epitope peptides and conjugates thereof for use in therapeutic compositions and assays |
| US20060205070A1 (en) * | 2004-01-13 | 2006-09-14 | The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services | HIV TEV compositions and methods of use |
| US8034773B2 (en) * | 2004-02-05 | 2011-10-11 | Arizona Biomedical Research Commission | Immunostimulatory compositions and uses thereof |
| US7927580B2 (en) | 2004-03-16 | 2011-04-19 | Nanirx, Inc. | Tat-based immunomodulatory compositions and methods of their discovery and use |
| FR2868318B1 (fr) * | 2004-04-01 | 2012-11-16 | Commissariat Energie Atomique | Antigene tat stabilise et ses applications pour la vaccination anti-vih |
| US8178649B2 (en) * | 2004-12-07 | 2012-05-15 | Arizona Biomedical Research Commission | Immunostimulatory compositions and uses thereof |
| WO2006088739A1 (en) * | 2005-02-15 | 2006-08-24 | Thymon, L.L.C. | Assays for detecting the tat protein in hiv-1 infection |
| JP2008535783A (ja) * | 2005-02-15 | 2008-09-04 | サイモン・エル・エル・シー | Ｈｉｖ−１の増殖を弱めるための方法および組成物 |
| WO2006089678A2 (en) * | 2005-02-22 | 2006-08-31 | Bioinvent International Ab | Antibodies and peptides binding to hiv tat, and uses thereof |
| AU2007284656A1 (en) * | 2006-08-14 | 2008-02-21 | Thymon, L.L.C. | Compositions and methods for the treatment and prophylaxis of multiple strains and subtypes of HIV-1 |
| US8460697B2 (en) * | 2006-12-13 | 2013-06-11 | Susavion Biosciences, Inc. | Pro-angiogenic peptides and uses thereof |
| US7811995B2 (en) * | 2006-12-13 | 2010-10-12 | Susavion Biosciences, Inc. | Therapeutic and diagnostic peptides |
| US8496942B2 (en) * | 2006-12-13 | 2013-07-30 | Susavion Biosciences, Inc. | Therapeutic peptides and uses thereof |
| USRE46425E1 (en) | 2006-12-13 | 2017-06-06 | Susavion Biosciences, Inc. | Pro-angiogenic peptides and uses thereof |
| US7838497B2 (en) * | 2006-12-13 | 2010-11-23 | Susavion Biosciences, Inc. | Pro-angiogenic peptides |
| US20110027315A1 (en) * | 2007-09-07 | 2011-02-03 | Allen Harmsen | Protein cages and their uses |
| CN101883858B (zh) | 2007-11-28 | 2015-07-22 | 宾夕法尼亚大学托管会 | 猿猴亚家族E腺病毒SAdV-39、-25.2、-26、-30、-37和-38及其应用 |
| CN102131920B (zh) | 2007-11-28 | 2013-11-06 | 宾夕法尼亚大学托管会 | 猿猴亚家族C腺病毒SAdV-40、-31和-34及其应用 |
| JP5661476B2 (ja) | 2008-03-04 | 2015-01-28 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | サルアデノウイルスＳＡｄＶ−３６、−４２．１、−４２．２および−４４ならびにそれらの用途 |
| WO2010051367A1 (en) | 2008-10-31 | 2010-05-06 | The Trustees Of The University Of Pennsylvania | Simian adenoviruses sadv-43, -45,-48,-49, and -50 and uses thereof |
| EP2411043B1 (en) | 2009-03-23 | 2013-07-31 | PIN Pharma, Inc. | Treatment of cancer with immunostimulatory hiv tat derivative polypeptides |
| CA2762203A1 (en) | 2009-05-29 | 2010-12-02 | Soumitra Roy | Simian adenovirus 41 and uses thereof |
| US20100322943A1 (en) | 2009-06-17 | 2010-12-23 | Thomas Cantor | Therapeutic and diagnostic affinity purified specific polyclonal antibodies |
| AU2011230619C1 (en) | 2010-03-25 | 2016-06-23 | Oregon Health & Science University | CMV glycoproteins and recombinant vectors |
| AU2011332025B2 (en) | 2010-11-23 | 2015-06-25 | The Trustees Of The University Of Pennsylvania | Subfamily E simian adenoviruses A1321, A1325, A1295, A1309 and A1322 and uses thereof |
| HUE037408T2 (hu) | 2011-06-10 | 2018-08-28 | Univ Oregon Health & Science | CMV glikoproteinek és rekombináns vektorok |
| CA2789539A1 (en) | 2011-09-12 | 2013-03-12 | International Aids Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies |
| US9402894B2 (en) | 2011-10-27 | 2016-08-02 | International Aids Vaccine Initiative | Viral particles derived from an enveloped virus |
| SG11201407343XA (en) | 2012-05-18 | 2014-12-30 | Univ Pennsylvania | Subfamily e simian adenoviruses a1302, a1320, a1331 and a1337 and uses thereof |
| ES2631608T3 (es) | 2012-06-27 | 2017-09-01 | International Aids Vaccine Initiative | Variante de la glicoproteína Env del VIH-1 |
| RU2653754C2 (ru) * | 2012-12-06 | 2018-05-14 | Пин Фарма, Инк. | Лечение воспалительных, аутоиммунных и нейродегенеративных нарушений иммуннодепрессивными полипетидами, являющимися производными тат |
| EP2848937A1 (en) | 2013-09-05 | 2015-03-18 | International Aids Vaccine Initiative | Methods of identifying novel HIV-1 immunogens |
| CN105705164A (zh) | 2013-10-04 | 2016-06-22 | 品诺制药公司 | 用于癌症治疗的免疫刺激性hiv tat衍生多肽 |
| US10058604B2 (en) | 2013-10-07 | 2018-08-28 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
| ES2833230T3 (es) | 2014-05-13 | 2021-06-14 | Univ Pennsylvania | Composiciones que comprenden AVV que expresan construcciones y usos de doble anticuerpo del mismo |
| EP3069730A3 (en) | 2015-03-20 | 2017-03-15 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
| US9931394B2 (en) | 2015-03-23 | 2018-04-03 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
| AU2022264509A1 (en) | 2021-04-27 | 2023-12-14 | Generation Bio Co. | Non-viral dna vectors expressing therapeutic antibodies and uses thereof |
| CN119072330A (zh) | 2022-03-14 | 2024-12-03 | 世代生物公司 | 异源初免加强疫苗组合物和使用方法 |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4405712A (en) * | 1981-07-01 | 1983-09-20 | The United States Of America As Represented By The Department Of Health And Human Services | LTR-Vectors |
| US4531167A (en) * | 1983-08-25 | 1985-07-23 | Pioneer Research, Inc. | Servowriter system for magnetic disc drives |
| US4738922A (en) * | 1984-05-25 | 1988-04-19 | Dana Farber Cancer Institute | Trans-acting transcriptional factors |
| US6858712B1 (en) * | 1984-08-22 | 2005-02-22 | The United States Of America As Represented By The Department Of Health And Human Services | Cloning and expression of HTLV-III DNA |
| US4871488A (en) * | 1985-04-22 | 1989-10-03 | Albany Medical College Of Union University | Reconstituting viral glycoproteins into large phospholipid vesicles |
| US5801056A (en) * | 1985-05-24 | 1998-09-01 | Dana-Farber Cancer Institute | Nucleic acid encoding HIV-1 tat protein |
| US4735896A (en) * | 1986-03-04 | 1988-04-05 | United Biomedical, Inc. | Synthetic peptide and process of using same for the detection and diagnosis of AIDS and pre-AIDS conditions |
| PT83682B (en) * | 1985-11-06 | 1988-12-05 | Smithkline Beckman Corp | Process for the expression of an aids virus gene |
| CS256960B1 (en) * | 1985-11-16 | 1988-04-15 | Viktor Krchnak | Peptides with properties of antigenic determinants and method of their production |
| US4812929A (en) * | 1985-11-19 | 1989-03-14 | Rodime Plc | Head positioning mechanism for rotating disk data storage system |
| US5306614A (en) * | 1986-01-22 | 1994-04-26 | Institut Pasteur | Methods and kits for diagnosing human immunodeficiency virus type 2(HIV-2) |
| US4839288A (en) * | 1986-01-22 | 1989-06-13 | Institut Pasteur | Retrovirus capable of causing AIDS, antigens obtained from this retrovirus and corresponding antibodies and their application for diagnostic purposes |
| US4983387A (en) * | 1986-05-19 | 1991-01-08 | Viral Technologies Inc. | HIV related peptides, immunogenic antigens, and use therefor as subunit vaccine for AIDS virus |
| US5030714A (en) * | 1986-06-23 | 1991-07-09 | Institut Pasteur | Variant of LAV viruses |
| US5166050A (en) * | 1986-08-20 | 1992-11-24 | Bristol-Myers Squibb Company | Monoclonal antibodies and peptides useful in treating and diagnosing HIV infections |
| US5476765A (en) * | 1987-01-09 | 1995-12-19 | United Biomedical, Inc. | Synthetic peptide compositions with immunoreactivities to antibodies to HTLV and as vaccines |
| US5026635A (en) * | 1987-05-19 | 1991-06-25 | Du Pont Merck Pharmaceutical | Stable human cell lines expressing an indicator gene product under virus-specific genetic controls |
| US5110802A (en) * | 1987-07-14 | 1992-05-05 | City Of Hope | Oligonucleotide phosphonates and method of inhibiting a human immunodeficiency virus in vitro utilizing said oligonucleotide phosphonates |
| US5019510A (en) * | 1987-10-28 | 1991-05-28 | Institut Pasteur | Isolation, molecular cloning and sequencing of an HIV-1 isolate from a Gabonese donor |
| US4888290A (en) * | 1987-11-06 | 1989-12-19 | Coulter Corporation | Monoclonal antibody specific to HIV antigens |
| US5831034A (en) * | 1987-11-13 | 1998-11-03 | Hermann Katinger | Human monoclonal anti-HIV-I-antibodies |
| US5606026A (en) * | 1988-03-25 | 1997-02-25 | The Institute For Human Genetics And Biochemistry | Natural human IgM antibodies immunoreactive with the Tat protein of HIV-1 |
| GB8808892D0 (en) * | 1988-04-15 | 1988-05-18 | British Bio Technology | Gene synthesis |
| US5043262A (en) * | 1988-05-12 | 1991-08-27 | Dana Farber Cancer Institute | Protein, sequences containing the VPU gene therefore, vectors, methods of preparation and use |
| DE3934366A1 (de) * | 1989-10-14 | 1991-04-18 | Chemotherapeutisches Forschungsinstitut Georg Speyer Haus | Vakzine zum schutz vor hiv-virusinfektionen, verfahren zu ihrer herstellung und ihre verwendung als diagnostikum und immuntherapeutikum |
| US5670617A (en) * | 1989-12-21 | 1997-09-23 | Biogen Inc | Nucleic acid conjugates of tat-derived transport polypeptides |
| JPH05505102A (ja) * | 1989-12-21 | 1993-08-05 | ホワイトヘツド・インスチチユート・フオー・バイオメデイカル・リサーチ | 真核細胞の中に分子を配達する方法 |
| US5804604A (en) * | 1989-12-21 | 1998-09-08 | Biogen, Inc. | Tat-derived transport polypeptides and fusion proteins |
| AU642959B2 (en) * | 1990-01-18 | 1993-11-04 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | Vector with multiple target response elements affecting gene expression |
| GB9003010D0 (en) * | 1990-02-09 | 1990-04-04 | Glaxo Group Ltd | Gene expression in yeast cells |
| US5527894A (en) * | 1990-06-11 | 1996-06-18 | Nexstar Pharmacueticals, Inc. | Ligands of HIV-1 tat protein |
| GB9016973D0 (en) * | 1990-08-02 | 1990-09-19 | Medical Res Council | Viral growth inhibition |
| ES2095959T3 (es) * | 1990-10-24 | 1997-03-01 | Allelix Biopharma | Inhibidores de la replicacion del virus vih a base de peptidos. |
| US5646120A (en) * | 1990-10-24 | 1997-07-08 | Allelix Biopharmaceuticals, Inc. | Peptide-based inhibitors of HIV replication |
| JPH06508603A (ja) * | 1991-02-14 | 1994-09-29 | ラ ホヤ キャンサー リサーチ ファウンデーション | ＨＩＶ Ｔａｔタンパク質に対する新規インテグリン特異性 |
| US5350835A (en) * | 1991-11-05 | 1994-09-27 | Board Of Regents, University Of Texas | Cellular nucleic acid binding protein and uses thereof in regulating gene expression and in the treatment of aids |
| DE69311764T2 (de) * | 1992-05-14 | 1998-02-05 | Polymun Scient Immunbio Forsch | Peptide, die Antikörper induzieren, die genetisch divergierende HIV-1 Isolationen neutralisieren |
| JPH08500965A (ja) * | 1992-05-22 | 1996-02-06 | デイナ ファーバー キャンサー インスチチュート | ハイブリッドウイルス発現ベクター，その使用および新規アッセイ |
| WO1994015634A1 (en) * | 1992-12-30 | 1994-07-21 | Matthias Rath | Tat and rev oligopeptides in hiv treatment |
| FR2700169B1 (fr) * | 1993-01-04 | 1995-03-24 | Transgene Sa | Nouveaux variants trans-dominants TAT du virus de l'immunodéficience humaine. |
| DE4405810A1 (de) * | 1994-02-23 | 1995-08-24 | Behringwerke Ag | Von einem Retrovirus aus der HIV-Gruppe abgeleitete Peptide und deren Verwendung |
| US5421412A (en) * | 1994-03-10 | 1995-06-06 | North Carolina State University | Methods and compositions for fracturing subterranean formations |
| WO1995031999A1 (en) * | 1994-05-23 | 1995-11-30 | Immunogiology Research Institute, Inc. | Compositions of transactivating proteins of human immunodeficiency virus |
| US5793559A (en) * | 1996-02-27 | 1998-08-11 | Quantum Corporation | In drive correction of servo pattern errors |
| SG52990A1 (en) * | 1996-07-09 | 1998-09-28 | Ibm | Improvements to radial self-propagation pattern generation for disk file servowriting |
| US5875064A (en) * | 1996-07-09 | 1999-02-23 | International Business Machines Corporation | Method and system for accurate self-servowriting with normalization in a disk drive |
| US6024965A (en) * | 1996-10-18 | 2000-02-15 | Erasums University Rotterdam | Induction of REV and TAT specific cytotoxic T-cells for prevention and treatment of human immunodeficiency virus (HIV) infection |
| US5891994A (en) * | 1997-07-11 | 1999-04-06 | Thymon L.L.C. | Methods and compositions for impairing multiplication of HIV-1 |
| US6023145A (en) * | 1999-04-21 | 2000-02-08 | Guzik Technical Enterprises | Head and disk tester with a thermal drift-compensated closed-loop positioning system |
| US6507450B1 (en) * | 1999-06-11 | 2003-01-14 | Western Digital Technologies, Inc. | Method of continuously recording servo bursts along one continuous, single helix spiral |
| US6519107B1 (en) * | 1999-09-24 | 2003-02-11 | Maxtor Corporation | Hard disk drive having self-written servo burst patterns |
| US6399067B1 (en) * | 2000-04-28 | 2002-06-04 | Thymon L.L.C. | Methods and compositions for impairing multiplication of HIV-1 |
| JP2008535783A (ja) * | 2005-02-15 | 2008-09-04 | サイモン・エル・エル・シー | Ｈｉｖ−１の増殖を弱めるための方法および組成物 |
-
1997
- 1997-07-11 US US08/893,853 patent/US5891994A/en not_active Expired - Lifetime
-
1998
- 1998-07-10 ES ES98934401T patent/ES2317668T3/es not_active Expired - Lifetime
- 1998-07-10 AT AT98934401T patent/ATE413189T1/de not_active IP Right Cessation
- 1998-07-10 AU AU83927/98A patent/AU745012C/en not_active Ceased
- 1998-07-10 WO PCT/US1998/014332 patent/WO1999002185A1/en not_active Ceased
- 1998-07-10 CA CA2295691A patent/CA2295691C/en not_active Expired - Fee Related
- 1998-07-10 JP JP2000501775A patent/JP4278293B2/ja not_active Expired - Lifetime
- 1998-07-10 DE DE69840195T patent/DE69840195D1/de not_active Expired - Lifetime
- 1998-07-10 US US09/113,921 patent/US6193981B1/en not_active Expired - Fee Related
- 1998-07-10 EP EP98934401A patent/EP0994724B1/en not_active Expired - Lifetime
-
1999
- 1999-11-30 US US09/451,067 patent/US6525179B1/en not_active Expired - Fee Related
-
2002
- 2002-02-28 US US10/086,208 patent/US7008622B2/en not_active Expired - Fee Related
- 2002-09-30 US US10/262,435 patent/US20030166832A1/en not_active Abandoned
-
2006
- 2006-07-24 US US11/491,755 patent/US20060258594A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2001509368A5 (https=) | ||
| JP2004514406A5 (https=) | ||
| RU2002131943A (ru) | Способы и композиции для ингибирования размножения вич-1 | |
| Löwenadler et al. | A gene fusion system for generating antibodies against short peptides | |
| CA2295691A1 (en) | Methods and compositions for impairing multiplication of hiv-1 | |
| Newton et al. | Immune response to cholera toxin epitope inserted in Salmonella flagellin | |
| JP4106041B2 (ja) | エプスタイン−バールウイルスに関連するペプチド及び核酸配列 | |
| Dunn | Assembly of functional bacteriophage lambda virions incorporating C-terminal peptide or protein fusions with the major tail protein | |
| AU750296B2 (en) | Antibodies against SEMP1, methods for their production and uses thereof | |
| AU652851B2 (en) | Hepatitis C virus from C-100-3 and env/core regions | |
| Matthews et al. | Immunogenically fit subunit vaccine components via epitope discovery from natural peptide libraries | |
| JP2005524386A (ja) | 抗ｅ型肝炎ウイルスモノクローナル抗体、又は結合性を有するそのフラグメント、及びそれらの使用 | |
| WO2008035217A2 (en) | Fusion proteins comprising two or more igg binding domains of streptococcal protein g. | |
| JPH04504719A (ja) | 合成緑膿菌線毛ペプチド及び関連するワクチン及び診断剤 | |
| Adam et al. | Characterization of intertype specific epitopes on adenovirus hexons | |
| KR102869920B1 (ko) | 면역글로불린의 fc 도메인에 대한 결합 친화도가 결여된 신규 삼중-나선 폴리펩티드 및 이의 용도 | |
| Montgomery et al. | Affinity maturation and characterization of a human monoclonal antibody against HIV-1 gp41 | |
| JPH02503916A (ja) | Ｈｉｖエンベロープ蛋白質に関連する合成ペプチド | |
| Roscoe et al. | Primate antibody response to immunotoxin: serological and computer-aided analysis of epitopes on a truncated form of Pseudomonas exotoxin | |
| AU655112B2 (en) | HCV peptide antigens and method of determining HCV | |
| Ståhl et al. | Engineered bacterial receptors in immunology | |
| Camperi et al. | Synthetic peptides to produce antivenoms against the Cys-rich toxins of arachnids | |
| Novella et al. | Use of substituted and tandem‐repeated peptides to probe the relevance of the highly conserved RGD tripeptide in the immune response against foot‐and‐mouth disease virus | |
| JP6808178B2 (ja) | ヒトパルボウイルスｂ１９抗原および抗体の同時検出方法及びキット | |
| Dunn et al. | Fine mapping of the binding sites of monoclonal antibodies raised against the Pk tag |